Zhang Hong-Yi, Kong Ya-Lin, Zhang Hong-Yi, He Xiao-Jun, Zhang Hui, Liu Cheng-Li, Zhao Gang, Xiao Mei, Zhang Xi-Dong, Feng Zhi-Qiang
Department of Hepatobiliary Surgery, General Hospital of Air Force PLA, Beijing 100036, China.
Hepatobiliary Pancreat Dis Int. 2008 Aug;7(4):418-21.
The incidence of hepatic portal cholangiocarcinoma is increasing and it is always associated with poor survival. This study analyzed an effective therapeutic method.
A retrospective analysis was made on 70 patients with hepatic portal cholangiocarcinoma admitted between January 2004 and February 2007 to the General Hospital of Air Force PLA.
Forty-seven patients had hepatic duct-jejunum anastomosis after resection of hepatic portal cholangiocarcinoma. Internal or external biliary drainage and canals for internal radiation were performed in those patients unfit for operation. Among the 70 patients, 5 died within 15 months, 27 survived more than 24 months, and the others survived 4-18 months.
Surgery is the primary therapeutic method for hepatic portal cholangiocarcinoma. Internal or external biliary drainage can prolong the life-span.
肝门部胆管癌的发病率呈上升趋势，且其生存率一直较低。本研究分析了一种有效的治疗方法。
对2004年1月至2007年2月间空军总医院收治的70例肝门部胆管癌患者进行回顾性分析。
47例患者在肝门部胆管癌切除术后行肝管空肠吻合术。对不适于手术的患者进行了内、外胆管引流及内照射通道治疗。70例患者中，5例在15个月内死亡，27例存活超过24个月，其余患者存活4 - 18个月。
手术是肝门部胆管癌的主要治疗方法。内、外胆管引流可延长生存期。
